ABT – 199 (Venetoclax)
ABT-199, also known as Venetoclax was discovered by an Australian team of Melbourne-based researchers, shows great promise for people with different subtypes of lymphoma.
An investigator-led trial combining the two novel and highly targeted anti-cancer drugs – ibrutinib and venetoclax is available in Australia to treat patients with mantle cell lymphoma.
Although mantle cell lymphoma is relatively uncommon in Australia, with a few hundred cases diagnosed each year, new treatments that are effective for this disease are usually also active against more common blood cancers such as chronic lymphocytic leukemia and other forms of non-Hodgkin lymphoma.
The promising signals seen so far suggest that this combination may have the potential to replace chemotherapy for a variety of lymphomas in the not-so-distant future.